Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy
出版年份 2023 全文链接
标题
Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy
作者
关键词
-
出版物
Frontiers in Immunology
Volume 14, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2023-06-26
DOI
10.3389/fimmu.2023.1212209
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report
- (2023) Dong-Wan Kim et al. Journal of Thoracic Oncology
- Phase 1 first-in-human study of dalutrafusp alfa, an anti–CD73-TGF-β-trap bifunctional antibody, in patients with advanced solid tumors
- (2023) Anthony W Tolcher et al. Journal for ImmunoTherapy of Cancer
- Hallmarks of Cancer: New Dimensions
- (2022) Douglas Hanahan Cancer Discovery
- Adenosine metabolized from extracellular ATP promotes type 2 immunity through triggering A2BAR signaling in intestinal epithelial cells
- (2022) Darine W. El-Naccache et al. Cell Reports
- Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors
- (2022) Emerson A. Lim et al. CLINICAL CANCER RESEARCH
- A2AR limits IL-15-induced generation of CD39+ NK cells with high cytotoxicity
- (2022) Guijie Kang et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma
- (2021) Pedro Rocha et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- ARC-8: Phase I/Ib study to evaluate safety and tolerability of AB680 + chemotherapy + zimberelimab (AB122) in patients with treatment-naive metastatic pancreatic adenocarcinoma (mPDAC).
- (2021) Gulam Abbas Manji et al. JOURNAL OF CLINICAL ONCOLOGY
- OA07.08 HUDSON: An Open-Label, Multi-Drug, Biomarker-Directed, Phase II Platform Study in Patients with NSCLC, who Progressed on Anti-PD(L)1 Therapy
- (2021) B. Besse et al. Journal of Thoracic Oncology
- Editorial: Purinergic Signaling and Inflammation
- (2021) Xiaoyi Yuan et al. Frontiers in Immunology
- Release of adenosine-induced immunosuppression: Comprehensive characterization of dual A2A/A2B receptor antagonist
- (2021) Katarzyna Dziedzic et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- ARC-6: A phase 1b/2, open-label, randomized platform study to evaluate efficacy and safety of etrumadenant (AB928)-based treatment combinations in patients with metastatic castrate-resistant prostate cancer (mCRPC).
- (2021) Sumit Kumar Subudhi et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and efficacy of the anti-CD73 monoclonal antibody (mAb) oleclumab ± durvalumab in patients (pts) with advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), or EGFR-mutant non-small cell lung cancer (EGFRm NSCLC).
- (2021) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy
- (2021) Lauren Giuffrida et al. Nature Communications
- The elegant complexity of mammalian ecto-5′-nucleotidase (CD73)
- (2021) Karel P. Alcedo et al. TRENDS IN CELL BIOLOGY
- Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma
- (2021) Darci Phillips et al. Nature Communications
- Adenosine signalling is prognostic for cancer outcome and has predictive utility for immunotherapeutic response
- (2020) Ben Sidders et al. CLINICAL CANCER RESEARCH
- CD73 on cancer-associated fibroblasts enhanced by the A2B-mediated feedforward circuit enforces an immune checkpoint
- (2020) Miao Yu et al. Nature Communications
- CD73 blockade promotes dendritic cell infiltration of irradiated tumors and tumor rejection
- (2020) Erik Wennerberg et al. Cancer Immunology Research
- The Expression of Adenosine A2B Receptor on Antigen-Presenting Cells Suppresses CD8+ T-cell Responses and Promotes Tumor Growth
- (2020) Siqi Chen et al. Cancer Immunology Research
- The adenosine pathway in immuno-oncology
- (2020) Bertrand Allard et al. Nature Reviews Clinical Oncology
- Glioma patient profiling reveals the dominant immune suppressive adenosine axis is refractory to immune function restoration
- (2020) Martina Ott et al. JCI Insight
- 348P First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 oleclumab (O) to the anti-PD-L1 durvalumab (D) and chemotherapy (ChT) as first line therapy for patients (pts) with metastatic triple-negative breast cancer (mTNBC)
- (2020) D. Eiger et al. ANNALS OF ONCOLOGY
- Inhibition of the Adenosine Pathway to Potentiate Cancer Immunotherapy: Potential for Combinatorial Approaches
- (2020) Elizabeth A. Thompson et al. Annual Review of Medicine
- Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy
- (2020) Roberta Turiello et al. Journal for ImmunoTherapy of Cancer
- CD73 expression on effector T cells sustained by TGF-β facilitates tumor resistance to anti-4-1BB/CD137 therapy
- (2019) Siqi Chen et al. Nature Communications
- Purine Release, Metabolism, and Signaling in the Inflammatory Response
- (2019) Joel Linden et al. Annual Review of Immunology
- CD73 Promotes Glioblastoma Pathogenesis and Enhances Its Chemoresistance via A2B Adenosine Receptor Signaling
- (2019) Angela Yan et al. JOURNAL OF NEUROSCIENCE
- CD73: an emerging checkpoint for cancer immunotherapy
- (2019) Siqi Chen et al. Immunotherapy
- A2B Adenosine Receptor and Cancer
- (2019) Zhan-Guo Gao et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Inhibition of the Adenosinergic Pathway in Cancer Rejuvenates Innate and Adaptive Immunity
- (2019) Juliana Hofstätter Azambuja et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer
- (2019) Lawrence Fong et al. Cancer Discovery
- Adenosine Metabolism: Emerging Concepts for Cancer Therapy
- (2019) Detlev Boison et al. CANCER CELL
- CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment
- (2019) Shi Yong Neo et al. JOURNAL OF CLINICAL INVESTIGATION
- Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma
- (2019) Sangeeta Goswami et al. NATURE MEDICINE
- Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models
- (2018) Robert D. Leone et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
- (2018) Daniele V. F. Tauriello et al. NATURE
- Pharmacology of Adenosine Receptors: The State of the Art
- (2018) Pier Andrea Borea et al. PHYSIOLOGICAL REVIEWS
- Immunomodulatory role of Keratin 76 in oral and gastric cancer
- (2018) Inês Sequeira et al. Nature Communications
- A2AR Antagonism with CPI-444 Induces Antitumor Responses and Augments Efficacy to Anti–PD-(L)1 and Anti–CTLA-4 in Preclinical Models
- (2018) Stephen B. Willingham et al. Cancer Immunology Research
- The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets
- (2017) Bertrand Allard et al. IMMUNOLOGICAL REVIEWS
- Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab
- (2017) Silvana Morello et al. Journal of Translational Medicine
- Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer
- (2017) Yusuke Inoue et al. Oncotarget
- A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment
- (2017) Melanie Mediavilla-Varela et al. NEOPLASIA
- Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses
- (2016) Arabella Young et al. CANCER CELL
- Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis
- (2016) D. Mittal et al. CANCER RESEARCH
- A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer
- (2016) Stephen M Hatfield et al. CURRENT OPINION IN PHARMACOLOGY
- Adenosine as a Multi-Signalling Guardian Angel in Human Diseases: When, Where and How Does it Exert its Protective Effects?
- (2016) Pier Andrea Borea et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- CD73 is associated with poor prognosis in HNSCC
- (2016) Zhen-Hu Ren et al. Oncotarget
- Activation of the A2B adenosine receptor in B16 melanomas induces CXCL12 expression in FAP-positive tumor stromal cells, enhancing tumor progression
- (2016) Claudia Sorrentino et al. Oncotarget
- CD73 Is Associated with Poor Prognosis in High-Grade Serous Ovarian Cancer
- (2015) Martin Turcotte et al. CANCER RESEARCH
- CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer
- (2015) B. G. Leclerc et al. CLINICAL CANCER RESEARCH
- CD73: A potential biomarker for anti-PD-1 therapy
- (2015) Paul A Beavis et al. OncoImmunology
- Blockade of A2b Adenosine Receptor Reduces Tumor Growth and Immune Suppression Mediated by Myeloid-Derived Suppressor Cells in a Mouse Model of Melanoma
- (2015) Raffaella Iannone et al. NEOPLASIA
- Myeloid Expression of Adenosine A2A Receptor Suppresses T and NK Cell Responses in the Solid Tumor Microenvironment
- (2014) C. Cekic et al. CANCER RESEARCH
- Adenosine A2A Receptors Intrinsically Regulate CD8+ T Cells in the Tumor Microenvironment
- (2014) C. Cekic et al. CANCER RESEARCH
- Role of TGF-β Signaling in Generation of CD39+CD73+Myeloid Cells in Tumors
- (2014) Sergey V. Ryzhov et al. JOURNAL OF IMMUNOLOGY
- Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs
- (2013) B. Allard et al. CLINICAL CANCER RESEARCH
- Requirement of NK cells for selective A2A receptor blockade to suppress CD73+ tumor metastasis
- (2013) Lei Qin et al. Immunotherapy
- Blockade of A2Areceptors potently suppresses the metastasis of CD73+tumors
- (2013) Paul A. Beavis et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis
- (2013) C. J. Desmet et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CD73 as a novel prognostic biomarker for human colorectal cancer
- (2012) Nan Liu et al. JOURNAL OF SURGICAL ONCOLOGY
- Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor
- (2011) Adam T. Waickman et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Adenosine promotes alternative macrophage activation via A2A and A2B receptors
- (2011) Balázs Csóka et al. FASEB JOURNAL
- Adenosinergic Regulation of the Expansion and Immunosuppressive Activity of CD11b+Gr1+ Cells
- (2011) S. Ryzhov et al. JOURNAL OF IMMUNOLOGY
- A2B Adenosine Receptor Blockade Enhances Macrophage-Mediated Bacterial Phagocytosis and Improves Polymicrobial Sepsis Survival in Mice
- (2011) B. G. Belikoff et al. JOURNAL OF IMMUNOLOGY
- The A2B Adenosine Receptor Impairs the Maturation and Immunogenicity of Dendritic Cells
- (2009) J. M. Wilson et al. JOURNAL OF IMMUNOLOGY
- A2B adenosine receptors in immunity and inflammation
- (2009) György Haskó et al. TRENDS IN IMMUNOLOGY
- Adenosine receptors in regulation of dendritic cell differentiation and function
- (2008) S. V. Novitskiy et al. BLOOD
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started